KaliVir Immunotherapeutics Announces FDA Clearance of Investigational New Drug (IND) for Systemic Oncolytic Virus ASP1012 for Phase I Clinical Trials for Locally Advanced or Metastatic Solid Tumors

On October 24, 2023 KaliVir Immunotherapeutics, Inc., a biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, reported clearance of an Investigational New Drug (IND) application by the United States Food and Drug Administration (FDA) to initiate a Phase 1 clinical study of ASP1012 in participants with locally advanced or metastatic solid tumors (Press release, KaliVir Immunotherapeutics, OCT 24, 2023, View Source [SID1234636320]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Discovered and developed by Kalivir and licensed to Astellas Pharma Inc. in December 2020, ASP1012 (formerly named VET2-L2) is a systemic oncolytic vaccinia virus therapy in which the virus is delivered intravenously and expresses Leptin-IL2 fusion protein as a therapeutic payload. The trial is expected to begin in Q1 2024.

"ASP1012 was the first candidate built from our unique Vaccinia Enhanced Template (VET) platform and we are thrilled to reach this important milestone," said Steve Thorne, Ph.D, Chief Scientific Officer and founder of Kalivir. "Our partnership with Astellas underscores our mission to bring critical cancer therapies to patients and we look forward to continued collaborations."

"Immuno-oncology is a core focus of the Astellas R&D strategy and enriching our pipeline with the oncolytic virus ASP1012 is a testament to our commitment to provide new options to treat cancers where there are no effective treatment options," said Peter Sandor, M.D., MBA, Senior Vice President and Primary Focus Lead, Immuno-Oncology, Astellas. "The combination of KaliVir’s expertise in oncolytic viruses and Astellas’ drug development capabilities has been a great partnership and it’s exciting to see the collaboration move forward in this way, bringing us one step closer to developing an immuno-oncology therapy for patients."

Nutcracker Therapeutics to Present Data for Two mRNA Drug Candidates at SITC 2023

On October 24, 2023 Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, reported two poster presentations: one on the company’s lead mRNA therapeutic candidate, NTX-250, which targets human papillomavirus (HPV)-driven cancers; the other on its latest therapeutic candidate, NTX-471, which targets CD47 and CCR4 (Press release, Nutcracker Therapeutics, OCT 24, 2023, View Source [SID1234636319]). These data will be presented at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s (SITC’s) 38th Annual Meeting & Pre-Conference Programs (SITC 2023) in San Diego, CA, from November 1 through 5, 2023.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Nutcracker’s presentation on NTX-250 will describe how its three RNA-encoded protein components (HPV E6/E7, IL-12, and LIGHT) work together to drive enhanced immune responses and tumor clearance in murine models of HPV-driven tumors, while also providing immunogenic memory. The presentation on NTX-471 will describe unique mRNA compositions that can selectively target CD47 on cancerous cells over those on red blood cells, potentially alleviating the anemic side effects seen with anti-CD47 drugs currently under development.

Poster Presentations at SITC (Free SITC Whitepaper) 2023

Title: mNTX-250, a novel multimodal HPV-16 mRNA-based therapeutic, induces potent anti-tumor responses and establishes HPV-16 specific immune memory
Abstract Number: 134
Session Date and Time: Saturday, Nov 4th, 2023 9:00 AM – 7:00 PM
Lead Author: Ou Li

Title: NTX-471, engineered multivalent SIRPa and bispecific SIRPa-antiCCR4 molecules demonstrate superior activity providing path for mRNA-expressed in vivo biologics
Abstract Number: 1359
Session Date and Time: Friday, November 3, 2023: 9:00 AM – 7:00 PM
Lead Author: Gunasekaran Kannan

Poster presentations will be accessible in person and virtually. All accepted abstracts will be available in a Journal for ImmunoTherapy of Cancer (JITC) supplement, which will be published on October 31 at 9:00 a.m. EST. For more information about SITC (Free SITC Whitepaper) 2023, please visit View Source

Ankyra Therapeutics Receives FDA IND and Health Canada CTA Approval to Advance First-In-Class Selective Anchored Immunotherapy Agent, ANK-101, into Human Trials in Solid Tumors

On October 24, 2023 Ankyra Therapeutics, a clinical stage biotechnology company pioneering anchored immunotherapies to treat cancer, reported approval of its investigational new drug (IND) application by the U.S. Food & Drug Administration (FDA) and clinical trial application (CTA) by Health Canada for its lead agent, ANK-101, a novel tumor-directed anchored immune medicine (Press release, Ankyra Therapeutics, OCT 24, 2023, View Source [SID1234636318]). The Company plans to initiate a first-in-human Phase I clinical trial of ANK-101 as a single agent in early 2024 at a limited number of clinical sites in the U.S. and Canada in patients with advanced solid tumors who have failed standard of care treatments.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ANK-101, an interleukin-12 (IL-12) cytokine anchored to aluminum hydroxide, is locally delivered and retained in the tumor microenvironment for several weeks where it mediates recruitment and activation of effector immune cells. Ankyra has demonstrated single agent activity of ANK-101 in preclinical studies of various solid tumors in mice as well as in canine melanoma (cANK-101) with a tolerable safety profile.

"By anchoring to and being retained at the tumor site, ANK-101 has the ability to avoid hallmark challenges of both systemic and intratumoral therapies, namely by preventing cytokine diffusion, effectively training the body to potently destroy cancer cells," said Howard L. Kaufman, MD, CEO and President of Ankyra Therapeutics. "We are very excited about the clearance of our CTA and IND, which will allow us to bring ANK-101 to patients who may benefit from this new approach to cancer treatment."

Joe Elassal, MD, MBA, Ankyra’s Chief Medical Officer, added "ANK-101 represents potential treatment benefit without unwanted side effects. Our hope is that by anchoring the IL-12 at the site of tumor growth, we will see therapeutic activity without systemic toxicity. We look forward to advancing our first-in-class asset to realize this vision, and to paving the way for anchored immunotherapy to safely deliver other biologically active agents in the future."

About ANK-101
ANK-101 is an anchored drug complex composed of interleukin-12 (IL-12) linked to aluminum hydroxide. ANK-101 enables local delivery of functional IL-12 to the tumor microenvironment where it remains biologically active for several weeks but does not diffuse into the systemic circulation, thereby avoiding systemic toxicity. Treatment with ANK-101 in animal models has been associated with recruitment and retention of tumor-specific CD8+ T cells, NK cells and M1 macrophages activating innate and adaptive anti-tumor immunity. ANK-101 is being evaluated for the treatment of advanced solid tumors alone and in combination with anti-PD-1 agents.

MAIA Biotechnology Announces 100% Disease Control in Second-Line Non-Small Cell Lung Cancer Demonstrating Impressive Positive Preliminary Efficacy Data for Ongoing THIO-101 Phase 2 Trial

On October 24, 2023 MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical stage company developing telomere-targeting immunotherapies for cancer, reported positive preliminary efficacy data from its ongoing Phase 2 clinical trial, THIO-101, evaluating THIO in patients with advanced Non-Small Cell Lung Cancer (NSCLC) in sequential combination with Regeneron’s anti-PD-1 cemiplimab (Libtayo) (Press release, MAIA Biotechnology, OCT 24, 2023, View Source [SID1234636317]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Key findings:

100% Preliminary DCR observed in second-line and 88% in third-line, in highly difficult-to-treat patients who already progressed through previous lines of treatment.
DCRs across all dose levels met the pre-determined statistical requirements earlier than expected to proceed to next stage of the trial.
"In NSCLC patients who received at least one line of therapy, DCRs have shown to be excellent predictors of overall survival.1 Observing 100% DCR to date in second-line treatment is unprecedented compared to DCRs for the SoC ranging from 53-64%,2" said Vlad Vitoc, M.D., MAIA’s Chief Executive Officer. "We have also observed unprecedented high DCRs in third-line, with an 88% control rate, with treatment of THIO followed by cemiplimab. The results are even more remarkable given patients in this population have previously failed treatment with a checkpoint inhibitor. Currently, there is no SoC for third-line, but previous studies have reported an approximate 30% DCR.3 These exceptional preliminary results underscore our confidence in advancing the trial to bring our novel treatment to advanced stage NSCLC patients."

1 Matsumoto H et al. Transl Lung Cancer Res. 2021 May; 10(5): 2278–2289

2 REVEL View Source

3 Journal of Thoracic Oncology (VOLUME 16, ISSUE 10, OCTOBER 2021), T. Beninato et al.

Study Disease Control Rates by Line of Treatment

Treatment Line Standard of Care Treatment DCR Treatment Line THIO + Libtayo (cemiplimab) DCR
NSCLC-1 pembrolizumab (KEYNOTE-024)
71%

NSCLC-1 TBD
NSCLC-2 ramucirumab + docetaxel (REVEL)
64%

NSCLC-2
100%

docetaxel monotherapy (REVEL)
53%

NSCLC-3 chemotherapy (RWD)
25-35%

NSCLC-3
88%

The Company presented the data at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2023 in Madrid, Spain, on October 23, 2023. Full preliminary data is detailed in the poster available here.

About THIO

THIO (6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2’-deoxyguanosine (THIO) induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. THIO-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment with THIO followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. THIO is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.

About THIO-101, Phase 2 Clinical Trial

THIO-101 is a multicenter, open-label, dose finding Phase 2 clinical trial. It is the first trial designed to evaluate THIO’s anti-tumor activity when followed by PD-(L)1 inhibition. The trial is testing the hypothesis that low doses of THIO administered prior to Regeneron’s anti-PD-1 cemiplimab (Libtayo) will enhance and prolong immune response in patients with advanced NSCLC who previously did not respond or developed resistance and progressed after first-line treatment regimen containing a checkpoint inhibitor. The trial design has two primary objectives: (1) to evaluate the safety and tolerability of THIO administered as an anticancer compound and a priming immune activator (2) to assess the clinical efficacy of THIO using Overall Response Rate (ORR) as the primary clinical endpoint. Treatment with cemiplimab followed by THIO has been generally well-tolerated to date in a heavily pre-treated population. For more information on this Phase II trial, please visit ClinicalTrials.gov using the identifier NCT05208944.

Elpiscience Announces Three Poster Presentations at Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

On October 24, 2023 Elpiscience Biopharmaceuticals, Inc. ("Elpiscience"), a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapies to benefit cancer patients worldwide, reported that it will have three poster presentations at the SITC (Free SITC Whitepaper) 2023 Annual Meeting taking place November 3-5, 2023, in San Diego (Press release, Elpiscience, OCT 24, 2023, View Source [SID1234636316]). The posters will highlight its studies on three innovative molecules including a first-in-class NKG2A/NKG2C dual-targeting antibody ES015, a high affinity LILRB1 specific blocking antibody ES008-a, and the first-in-class anti-CD39/TGF-βRII bifunctional fusion protein ES014 which has been proven to be able to deliver TGFβ "trap" to CD39-expressing immune and stroma cells to reshape tumor microenvironment and rejuvenates antitumor immunity.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster presentation details:

Title: Selective delivery of TGFβ "trap" to CD39-expressing immune and stroma cells reshapes tumor microenvironment and rejuvenates antitumor immunity
Abstract Number: 453
Date and time: November 3, 2023; 9 am –7 pm PDT
Location: Exhibit Halls A and B1 – San Diego Convention Center

Title: ES015, a first-in-class NKG2A and NKG2C dual-targeting antibody, demonstrated potent anti-tumor immune response
Abstract Number: 498
Date and time: November 4, 2023; 9 am –8:30 pm PDT
Location: Exhibit Halls A and B1 – San Diego Convention Center

Title: ES008-a, a high affinity LILRB1 specific blocking antibody activates multiple immune cells to fight cancers
Abstract Number: 510
Date and time: November 4, 2023; 9 am –8:30 pm PDT
Location: Exhibit Halls A and B1 – San Diego Convention Center